Regen BioPharmaRGBP +33.33% Market Cap is $0.10 Mil as of Jun. 26, 2026. The stock has 7 warning signs investors should review. Among 1,431 Biotechnology companies, Regen BioPharma ranks worse than 99.93% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Regen BioPharma's share price for the quarter that ended in Mar. 2026 was $0.0007. Regen BioPharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 351.44 Mil. Therefore, Regen BioPharma's market cap for the quarter that ended in Mar. 2026 was $0.25 Mil.
Regen BioPharma's quarterly market cap
increased
from Sep. 2025 ($0.53 Mil) to Dec. 2025 ($0.80 Mil) but then
declined
from Dec. 2025 ($0.80 Mil) to Mar. 2026 ($0.25 Mil).
Regen BioPharma's annual market cap
declined
from Sep. 2023 ($6.33 Mil) to Sep. 2024 ($1.08 Mil) and
declined
from Sep. 2024 ($1.08 Mil) to Sep. 2025 ($0.53 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Regen BioPharma's Enterprise Value for Today is $1.08 Mil.
Regen BioPharma (OTCPK:RGBP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Regen BioPharma Market Cap Related Terms
Regen BioPharma Market Cap Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Regen BioPharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Regen BioPharma's Market Cap for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a Market Cap of $0.10 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #1430 out of 1431 companies in the Biotechnology industry, placing it in the top 99.9%.
Is Regen BioPharma's Market Cap too high?
Regen BioPharma's current Market Cap is $0.10 Mil. The Biotechnology industry median Market Cap is 113.83. Regen BioPharma's value of $0.10 Mil is 99.9% below this industry median. Based on the distribution chart, Regen BioPharma ranks #1430 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's Market Cap compare to ENDV and ADTX?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #1430 out of 1431 companies for Market Cap. This places Regen BioPharma in the lower half of its industry. The industry median Market Cap is 113.83. Regen BioPharma's value of $0.10 Mil is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regen BioPharma's current Market Cap of $0.10 Mil is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Regen BioPharma and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current Market Cap is $0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Market Cap is $0.10 Mil and 99.9% below the Biotechnology industry median of 113.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Market Cap is $0.10 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 